VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd

Bullboard Posts

Comment by jpinkmanon Jul 17, 2018 3:50pm

91 Views

Post# 28328993

RE:RE:RE:Maz Starts Study Comparing VPT to Contrast Enhanced 2D Echo

how about this part??

Annayya wrote: Sharing the letter from February 21st again. If anyone got a new letter today please post here so we can have some clarity on the number of studies at Maz. As I read this letter again it appears that it was always a plan for this comparison to contrast-enhanced 2D Echo study to happen. So I don't think this is the third study.

Since this study was just started they must have been busy with the other study for the past five months which I think has to do with children. Starting a new study probably means they are done with the other study. They now need to just use all the data, write a paper, and publish it.

Dear Stakeholder;

Attached is a new release announcing our first installation of a VMS+ system at “The Maz" in Edmonton. Here is some background information.

1. The Maz had an original VMS for RV only and now has upgraded to the VMS+ for all 4 chambers of the heart.
2. As usual, they want to try it out on a select group of patients until they adopt it for everyone. Accordingly, they are going to study “technically-difficult” patients first and then cancer patients.
3. "Technically-difficult” is jargon for patients (30-40% of people), who give poor quality images, but as you know the VMS+ excels at analyzing studies where only a small area in each of the 16 normal views can be discerned. It is by aggregating all these little bits of information and using an AI approach we can get the correct result.
4. We have been encourage by our expert users, who have been surprised to be able to analyze what they would have previously said were “unreadable” echocardiograms.
5. Normally, such patients would have gone on to have contrast media injected and have the study redone. This is dangerous (allergic reaction to contrast media), expensive, traumatic and time-consuming, as it requires an IV nurse to be summoned and waited for and numerous people, especially children do not like needles.
6. We continue our quest to improve cardiac diagnosis for all, especially for children. While we originally wanted to avoid MRI, we now see the potential to eliminate needles and contrast media.
7. The study will not take long as the Maz is a busy cardiac centre and so we should have something to report Soon
8. As usual, call me or send me message of you have questions.

Thanks for your continued support and interest in VPT.

Regards,

George Adams, PhD, ICD.D
CEO
Ventripoint Diagnostics Ltd..
Cell: 519-803-6937
TSXV: VPT
www.ventripoint.com
The world's first •dot imaging• company
Read more at https://www.stockhouse.com/companies/bullboard?symbol=v.vpt&postid=27594118#5UOT7MP0O7diXbOI.99